CN105906705A - CD19 immunogen polypeptide and application thereof - Google Patents

CD19 immunogen polypeptide and application thereof Download PDF

Info

Publication number
CN105906705A
CN105906705A CN201610438413.7A CN201610438413A CN105906705A CN 105906705 A CN105906705 A CN 105906705A CN 201610438413 A CN201610438413 A CN 201610438413A CN 105906705 A CN105906705 A CN 105906705A
Authority
CN
China
Prior art keywords
cell
polypeptide
tumor
immunogen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610438413.7A
Other languages
Chinese (zh)
Inventor
罗瑞雪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Puluoda Biological Science and Technology Co Ltd
Original Assignee
Suzhou Puluoda Biological Science and Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Puluoda Biological Science and Technology Co Ltd filed Critical Suzhou Puluoda Biological Science and Technology Co Ltd
Priority to CN201610438413.7A priority Critical patent/CN105906705A/en
Publication of CN105906705A publication Critical patent/CN105906705A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention belongs to the field of anticancer vaccines, discloses a CD19 immunogen polypeptide, particularly relates to an optimization polypeptide for the CD19 immunogen of an anticancer vaccine for enhancing T cell immunologic response and particularly relates to application of preparing medicine for tumor immune cells and T cell immune response enhancement and application of preparing medicine for CAR-T cell immune therapy, wherein an amino acid sequence is adopted as a brand new sequence and applied to preparing medicine for treating tumors. The CD19 immunogen polypeptide has the advantages that the brand new sequence is adopted, the CD19 immunogen polypeptide can be used for the immunogen for the tumor immune cell technology, T cells can be promoted, CD8+ immune response can be promoted, effective specific binding with MHC on the surfaces of the T cells can be achieved, binding of the T cells and tumor cells can be promoted, and tumor growth can be restrained inside tumor-bearing mice. The CD19 immunogen polypeptide is adopted as a target molecule of the cell therapy and applied to CAR-T and other cell therapies.

Description

A kind of CD19 immunogene polypeptide and application thereof
Technical field
The present invention is relevant anti-cancer vaccine field.In particular it relates to be used as the CD19 of anti-cancer vaccine Immunogenic optimization polypeptide, strengthens T cell immune response.
Background technology
B cell lymphoma is that the entity tumor that B cell occurs typically occurs in children and adult, is that one is attacked Hit the cancer types of B cell in immune system.Including Hodgkin lymphoma and NHL.Its parting Numerous, classical Hodgkin lymphoma and Nodular lymphocyte are principal mode Hodgkin lymphoma, are presently considered to be Originate from the tumour of B cell.Diffusivity large B cell lymphoid tumor, follicular lymphoma, mucosa-associated lymphoid group Knit lymthoma (MALT), small lymphocyte lymthoma/chronic lymphocytic leukemia, lymphoma mantle cell (MCL) 5 kinds of B cell NHLs are most commonly seen, account for the 3/4 of NHL.B cell lymphoma Prognosis and treatment depend on lymphadenomatous particular type and stage and step.Current treatment means with chemotherapy are Main, but chemotherapy is very big to actual bodily harm, later rehabilitation passive protective physical fitness also can become very poor.
Researcher finds that B cell lymphoma cell surface receptor CD19 plays key effect.CD19 is one Plant B cell specific transferring film glycoprotein, be expressed in B system cell (not including mature plasme cell) and follicular dendritic On shape cell, CD19 is a kind of important signal transduction molecule, the growth activation of regulation bone-marrow-derived lymphocyte and work Change, regulation bone-marrow-derived lymphocyte antigen receptor or other surface receptors signal threshold value in play an important role, be with Bone-marrow-derived lymphocyte breaks up, activate, breed and antibody produces relevant important membrane antigen, is diagnosis bone-marrow-derived lymphocyte It is the preferably mark of tumour, such as chronic lymphocytic leukemia (CLL) and ALL (ALL).
There is the antibody of the clinical trial testing antagonism CD19 acceptor of tumour at present.This antibody can not only kill Dead bone-marrow-derived lymphocyte system tumour, B cell that the most also can be healthy, thus weaken immune system.Researcher wishes Prestige can design more effective methods for the treatment of, can optionally kill tumour cell, retains the B of health simultaneously Cell, produces clinical therapeutic efficacy safer, effective.
Tumour cell immunization therapy be a kind of emerging, there is the tumor treatment model of significant curative effect, be a kind of from The novel method for the treatment of of body immunity anticancer.It uses biotechnology and biologic product to gathering from the patient The method that immunocyte feeds back in patient body after carrying out in vitro culture and amplification, excites, and strengthens body self Immunologic function, thus reach to treat the purpose of tumour.Tumour cell immunotherapy is continue operation, radiation and chemotherapy The fourth-largest oncotherapy technology afterwards.
CD19 can be as the specific immunogens of tumor vaccine.But, CD19, by the albumen of 95KDa, divides Son amount is bigger, it is more difficult to obtain the CD19 that purity is high.So, the Specific T cell immunity in later stage can not only be given Bring difficulty, and the autoimmunity of patient can be caused.Therefore, the invention provides a kind of high specificity, pure Spend higher micromolecule polypeptide as immunogene.
Summary of the invention
Goal of the invention
The present invention provides a kind of CD19 immunogene polypeptide, can be used for the immunogene of tumour cell immunity, strengthens T Cellullar immunologic response, has the advantages that molecular weight is little, specific immunogenic is strong.
Technical scheme
Technical program of the present invention lies in providing a kind of CD19 immunogene polypeptide, sequence is DNAVLQCLKGTSDGPTQQLTWSRESPLK FLKLSLGLPGLGIHMRPLASW (SEQ ID NO:1).This amino acid sequence is brand-new sequence, in preparation in tumor Application.Especially in preparation for tumor vaccine cells, strengthen the application in T cell immune response medicine, And the application of CAR-T cellular immunotherapy it is used in preparation.
Beneficial effect
The CD19 immunogene polypeptide of the present invention, for brand-new sequence, can be used in tumor vaccine cells technology Immunogene.Having the beneficial effects that (1) promotes T cell, (2) promote CD8+ immune response, (3) energy and T The MHC of cell surface is the most specific binding, and (4) promote the combination of T cell and tumour cell, (5) In tumor-bearing mice body, the growth of tumour can be suppressed.As the target molecules of cell therapy, it is applied to CAR-T Etc. cell therapy.
Detailed description of the invention
Polypeptide is by Shanghai raw work gill synthesis.
Embodiment 1
The proliferation function of T lymphocyte: aseptic take mouse spleen, 1640 culture mediums clean 3 times, and 5ml injects Device core grinds, and 200 eye mesh screens filter, and make single cell suspension, and centrifugal (1000r/min, 5min) abandons Clearly, Tris-NH4CL cracks red blood cell, and ice-water bath stands 3-5min, centrifugal (1000r/min, 5min), abandons Supernatant, with aseptic cold PBS washed cell twice.The RPMI 1640 being eventually adding 10% calf serum cultivates Liquid (5ml) suspension cell, cell count, adjusting cell concentration is 5 × 106Individual/ml, in 96 well culture plates Middle cultivation.
Experiment set blank group, model group (concanavalin A, sigma company buy), each dosage of polypeptide (3, 6,12mg/ml) group.After each group is separately added into spleen lymphocyte suspension 100 μ l/ hole, blank group adds RPMI-1640 100 μ l, model group adds ConA (final concentration of 5 μ g/ml), and polypeptide each dosage group is adding ConA (final concentration of 5 μ g/ml) is added on the basis of the polypeptide of variable concentrations.37 DEG C of cell culture incubator static gas wave refrigerator 48h, cultivates every hole after terminating and adds 20 μ l MTT, continue to cultivate 4h, finally discard all solution in every hole, often Hole adds 100 μ lDMSO, concussion, with ELIASA detection 570nm at OD value, every hole set 5 parallel.
Table 1 polypeptide proliferation function to T lymphocyte
* P < 0.05, * * P < 0.01 is compared with model group.
Experimental result is shown in Table 1, compares with model group, and many Toplink promote the propagation of mouse spleen lymphocyte, Dosage be 3~12mg/ml scope present good dose-dependence, with the rate of increase of 20mg/ml Height, is 153.6%.
Embodiment 2
The immunogenicity determining of CD19 immunogene polypeptide: use Flow Cytometry to measure immunogene polypeptide pair The impact of CD8+T cell.6-8w C57BL/6 in age mouse, mouse is randomly divided into 4 groups, often group 10.(1) Blank group;(2) immunogene polypeptide low dose group;(3) dosage group in immunogene polypeptide;(4) polypeptide high dose Group.At the 0th, 7,14 days of test, carry out immunity respectively.Scheme is: blank group adds same volume 1,2,4mg/Kg solvent, experimental group polypeptide sets 3 dosage:, multiple spot note near mouse back lymph node Penetrate.After 30 days, eyeball takes blood 0.8ml, anticoagulant heparin, takes haemocyte layer, split with red blood cell after centrifugal for blood Solve liquid and crack red blood cell, wash away the red blood cell of cracking, then (purchase with the anti-CD8+-FITC of fluorescently-labeled monoclonal From Beijing Hua Taixin bio-medical technology Co., Ltd) hatch, fixing after, carry out Flow Cytometry mensuration, Evaluate the impact on CD8+T cell of the immunogene polypeptide.
The effect to CD8+T lymphocyte of table 2 polypeptide
* P < 0.05, * * P < 0.01 is compared with model group.
Experimental result is shown in Table 2, compares with blank group, and many Toplink promote mouse CD8+T lymphocyte, at dosage Be 1~4mg/Kg scope present good dose-dependence, the rate of increase with 4mg/Kg is the highest, for 156.82%.
Embodiment 3
Application competitive receptor-ligand affine method test polypeptide and the binding ability of MHC:
Binding ability various with HLA for polypeptide is judged by the competitive affine method of receptor-ligand.Will be fixing dense Degree is polypeptide and the polypeptide addition reaction of variable concentrations (1-50 μm ol/L) of the mark 125I of 50 μm ol/L (phosphate buffer and MHC, described MHC kit is purchased from the upper ingression limited public affairs of Ke's biotechnology to system , there are HLA-A1, A2, A3, A11 and A24 in department in kit), reaction system is formed two kinds of compounds, I.e. candidate polypeptide MHC compound and 125I labeling polypeptide compound.Candidate polypeptide is competing with 125I labeling polypeptide Strive the combination with MHC.Separate free many with hyperfiltration (product type Microcon 30, Amicon company) Peptide and polypeptide MHC compound, then measure the 125I exit dose of polypeptide MHC compound, by this exit dose Compare with the exit dose of the polypeptide MHC compound (not adding the sample of candidate polypeptide) not having Reverse transcriptase, Ask candidate polypeptide at suppression 50% labeling polypeptide concentration when MHC is combined, i.e. IC50.Thus obtain, many Peptide is respectively 8.67,6.87,3.22,6.53 to the IC50 value of HLA-A1, A2, A3, A11 and A24 With 0.22 μm ol/L, all meet the standard (≤10 μm ol/L) of positive polypeptides.Therefore, polypeptide is for having effectively The immunogene polypeptide of binding ability.
Embodiment 4
The T cell binding tests of CD19 immunogene polypeptide: use rosette to evaluate T cell and people Diffuse Large B-Cell Lymphoma (diffuse large B-cell lymphoma, DLBCL) activating B cell The binding ability of (activated B-cell, ABC) type cell line OCI-Ly3.Aseptic take Thymus of Guinea Pigs, 1640 Culture medium cleans 3 times, and 5ml piston grinds, and 200 eye mesh screens filter, and make single cell suspension, centrifugal 1000 revs/min, 10 minutes, abandon supernatant, adjust cell concentration for 3 × 10 with Hank ' s liquid6/ml.In 96 holes Culture plate is cultivated.
Experiment sets blank group, each dosage of polypeptide (3,6,12mg/ml) group.Each group is separately added into thymus gland and drenches Behind bar cell suspension 100 μ l/ hole, blank group adds RPMI-1640 500 μ l, and polypeptide each dosage group is adding The polypeptide of variable concentrations.37 DEG C of cell culture incubators, cultivate 48h, cultivate and add 100 μ l/ holes in every hole after terminating (cell concentration is 1 × 10 to OCI-Ly3 cell6/ ml, containing 10% hyclone), mixing, 500 revs/min, centrifugal 5 minutes.Abandoning supernatant, add a small amount of glutaraldehyde, rock gently, make cell suspend, add violet stain, 400 show Micro mirror is observed.The T lymphocyte of all more than 3 tumour cells of combination is garland positive cell.Count 100 T Cell is formed the lymphocyte percentage of garland, is the Percentage bound of T cell and OCI-Ly3 cell.Every hole sets 5 parallel.
Experimental result is shown in Table 3, compares with blank group, and CD19 immunogene polypeptide can increase T cell with conspicuousness With the Percentage bound (P < 0.01) of OCI-Ly3 cell, the Percentage bound of low middle high dose group is respectively 34.35,45.30 With 54.72%.Good dose-dependence is presented in the scope that dosage is 3~12mg/ml.
The impact that T cell is combined by table 3 polypeptide
* P < 0.05, * * P < 0.01 is compared with blank group.
Embodiment 5
The internal vigor of employment diffusivity large B cell lymphoid tumor Transplanted tumor model detection CD19 immunogene polypeptide.
6-8 SCID mice in age, mouse is randomly divided into 4 groups, male and female half and half, often group 10.(1) blank group; (2) polypeptide low dose group;(3) dosage group in polypeptide;(4) polypeptide high dose group.Set up people's diffusivity big B cell lymphoma Transplanted tumor model, the 3rd, 5,7 days after inoculated tumour cell, carry out immunity respectively. 1,2,4mg/Kg scheme is: blank group adds the solvent of same volume, and experimental group polypeptide sets 3 dosage:, Multi-point injection around tumour.After 21 days, observe mouse survival quantity, calculate survival rate.Result shows, Dosage 1,2, the polypeptide of 4mg/Kg can effectively protect mouse, improve the survival rate of tumor-bearing mice, survival rate Reach 65.87,70.98 and 82.98%.
SEQUENCE LISTING
<110> Pu Luoda bio tech ltd, Suzhou
<120> A kind of CD19 immunogene polypeptide and application thereof
<130>
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 37
<212> PRT
<213> Artificial sequence
<400> 1
Asp Asn Ala Val Leu Gln Lys Lys Lys Leu Ser Asp Gly Pro Thr Gln
1 5 10 15
Gln Leu Thr Trp Ser Arg Glu Ser Pro Leu Lys Leu Leu Leu Ser Leu
20 25 30
Gly Leu Pro Gly Leu
35

Claims (4)

1. a CD19 immunogene polypeptide, it is characterised in that: described peptide sequence is SEQ ID NO:1.
Polypeptide the most according to claim 1 is in the application in tumor.
Application the most according to claim 2, it is characterised in that: described polypeptide for tumor vaccine cells, strengthens the application in T cell immune response medicine in preparation.
Application the most according to claim 2, it is characterised in that: the application of CAR-T cellular immunotherapy it is used in preparation.
CN201610438413.7A 2016-06-19 2016-06-19 CD19 immunogen polypeptide and application thereof Pending CN105906705A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610438413.7A CN105906705A (en) 2016-06-19 2016-06-19 CD19 immunogen polypeptide and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610438413.7A CN105906705A (en) 2016-06-19 2016-06-19 CD19 immunogen polypeptide and application thereof

Publications (1)

Publication Number Publication Date
CN105906705A true CN105906705A (en) 2016-08-31

Family

ID=56750490

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610438413.7A Pending CN105906705A (en) 2016-06-19 2016-06-19 CD19 immunogen polypeptide and application thereof

Country Status (1)

Country Link
CN (1) CN105906705A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111544585A (en) * 2019-02-11 2020-08-18 北京卡替医疗技术有限公司 Adjuvant capable of boosting immune cells to expand in vivo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101612126A (en) * 2009-07-21 2009-12-30 浙江大学 The preparation and the purposes of CD19 monoclonal antibody immunity liposome
CN101943704A (en) * 2010-04-30 2011-01-12 北京大学人民医院 Novel application of anti-CD19 antibody and anti-CD5 antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101612126A (en) * 2009-07-21 2009-12-30 浙江大学 The preparation and the purposes of CD19 monoclonal antibody immunity liposome
CN101943704A (en) * 2010-04-30 2011-01-12 北京大学人民医院 Novel application of anti-CD19 antibody and anti-CD5 antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
冯元怡等: "ConA刺激小鼠T淋巴细胞期事件研究", 《北京医科大学学报》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111544585A (en) * 2019-02-11 2020-08-18 北京卡替医疗技术有限公司 Adjuvant capable of boosting immune cells to expand in vivo
WO2020164465A1 (en) * 2019-02-11 2020-08-20 北京卡替医疗技术有限公司 Adjuvant capable of promoting expansion of immune cells in vivo

Similar Documents

Publication Publication Date Title
KR102223873B1 (en) A BCMA Chimeric Antigen Receptor Based on Single Domain Antibody and Use therefore
KR100767554B1 (en) Cancer antigens based on tumor suppressor gene wt1 product
KR100235849B1 (en) Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
CN109096396A (en) A kind of anti-PD-L1 humanization nano antibody and its application
KR20230079259A (en) Screening and anti-tumor use of KRAS mutation-specific T-cell receptors
CN110267978A (en) The T cell of the IL-12 of expression film anchoring for treating cancer
CN107034235A (en) Joint targeting PD 1 and EGFR mosaic antigens T cells tumour immunity method
Churlaud et al. Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer
BR112020002816A2 (en) T cell activation method for cancer treatment
JP7384896B2 (en) Major Histocompatibility Complex (MHC) Class II-expressing Cancer Cell Vaccines and Methods of Use to Generate an Integrated Immune Response
CN107488235A (en) A kind of preparation and application of new enhanced antigen combined polypeptid induction liver cancer-specific CTL cells
CN106243213A (en) A kind of tumor associated antigen XAGE 1b small peptide and application
CN109265565A (en) It is a kind of carry molecular switch anti-CD79b Chimeric antigen receptor and its modification immunocyte and application
CN109370992A (en) A kind of purification process of universal CAR-T cell
CN102370979B (en) Building method for autovaccine by aiming at human TNF(Tumor Necrosis Factor)-alpha molecule
CN105906705A (en) CD19 immunogen polypeptide and application thereof
CN105132371A (en) Method for in vitro presenting and activating DC cells and application of method
CN106008695A (en) CD19 immunogen polypeptide and application thereof
CN110559424A (en) Application of outer membrane protein in preparation of malignant tumor immunotherapy medicine
CN105968189A (en) B and T lymphocyte attenuator immunogen polypeptide and application thereof
CN107281474A (en) Strengthen the New Immunity Strategy and immune composition of anti tumor immune response
CN113980133A (en) Antibody and application thereof in anti-tumor
CN106084033A (en) CD19 immunogen polypeptide and application thereof
CN106336456A (en) CD33 immunogenic polypeptide and application thereof
CN102838679B (en) The preparation and application of Her2 neu antigen positive tumor therapeutic vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160831

WD01 Invention patent application deemed withdrawn after publication